JEMO-PHARM A/S: Financial statements 2023
CVR: 10216109
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
JEMO-PHARM A/S (CVR 10216109) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 12,326,000 and a net result of DKK -560,000 compared with DKK -930,000 the year before. That is an increase of 22.3% compared with the year before. Equity in the 2023 report amounted to DKK -160,000. The company had 32 employees in the financial year.
- Gross Profit
- DKK 12,326,000
- Profit/Loss
- DKK -560,000
- Equity
- DKK -160,000
- Total Assets
- DKK 42,630,000
- Employees
- 32
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 12.3 mio. | -560 t. | -160 t. | 32 |
| 2022 | - | 10.1 mio. | -930 t. | -364 t. | 29 |
| 2021 | - | 11.5 mio. | 166 t. | 566 t. | 28 |
| 2020 | - | 8.6 mio. | -2.8 mio. | 400 t. | 24 |
| 2019 | - | 5.9 mio. | -6.1 mio. | -3.5 mio. | 25 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of September 26, 2023, MAM Invest ApS is registered as an owner of JEMO-PHARM A/S with an ownership share of 10%.
JEMO-PHARM A/S has published its annual report for 2022. Gross profit came to DKK 10,078,000, and the net result was DKK -930,000.
About JEMO-PHARM A/S
JEMO-PHARM A/S is a Danish company of the type Aktieselskab based in Stege, founded in 1986. The company is registered under the industry Fremstilling af andre fødevarer i.a.n.. The company was previously named CMA TERADATA A/S and TERADATA A/S. The management consists of Mikael Andreas Mohr. The board consists of Svend Aage Dreist Hansen (chair), Henrik Winther Olsen and Mikael Andreas Mohr. The company is owned by THE WHOLE COMPANY A/S and MAM Invest ApS. The company has 31 employees (2026). In 2025, the company reported a gross profit of DKK 11,929,000 and a net result of DKK 30,000 compared with DKK -8,629,000 the year before. Equity in the 2025 report amounted to DKK 10,041,000.